Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.